New PET tracer aims to spot multiple cancers in one scan

NCT ID NCT07144748

Recruiting now Diagnosis Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing a new radioactive tracer called 68Ga-NYM096 in 120 adults with various cancers. Participants receive one injection of the tracer followed by a PET/CT scan to see how well it highlights both primary tumors and cancer that has spread. The goal is to identify which cancers show up best on the scan, which could help guide future use of this imaging tool.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-NYM096 (a radioactive tracer for PET/CT imaging)
What this could lead to: If successful, this could lead to better ways to detect and monitor many types of cancer using a single imaging agent.
What could go wrong: This is an early imaging study, not a treatment trial. It may not show clear benefits for all cancer types, and the tracer may not work as hoped in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER

Contacts and locations

Locations

Peking Union Medical College Hospital, Beijing, Beijing 100730
RECRUITING

Beijing, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.